New biopharma firm to be established in Cambridge, UK following finance round.
M2 PHARMA-February 10, 2017-New biopharma firm to be established in Cambridge, UK following finance round
(C)2017 M2 COMMUNICATIONS
Some GBP8.75m has been raised in a funding round for new Cambridge, UK based biopharmaceutical company SuperX Ltd., Cambridge News reported on Friday.
Founder and acting chief medical officer, Trevor Baglin, previously worked alongside David Grainger and Jim Huntington to create XO1, an organisation acquired by Janssen Pharmaceuticals - one of Johnson & Johnson's subsidiaries - in March 2015.
Their latest entity - SuperX - will focus on developing new and unusual approaches for blocking thrombosis that causes heart attacks and strokes. The team said in a statement that unusual "experiments of nature have shone a light on the intricacies of blood coagulation pathways that have evaded conventional reductionist science for decades" and they hope to "deliver the ideal anticoagulant treatment for chronic use".
The new venture was launched following the Series A investment round, which included investments from Medicxi and Johnson & Johnson Innovation (NYSE: JNJ).
Kevin Johnson, a partner at Medicxi who is set to serve as chairman of the SuperX board, commented on the news: "We are delighted to have another opportunity to back a team with a proven track record in early-stage drug discovery, with a unique vision of how the anticoagulant drug space will develop over the next decade.
"Their virtual drug development model is a perfect fit with the asset-centric strategy we have championed at Medicxi."
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 10, 2017|
|Previous Article:||Quotient Limited appoints Christopher Lindop as chief financial officer.|
|Next Article:||Merck Foundation selects six programme grant recipients for Alliance to Advance Patient-Centered Cancer Care.|